Cannabinoids in the treatment of epilepsy

New England Journal of Medicine

Volumn 373, Issue 11, 2015, Pages 1048-1058

  Friedman, Daniel ^a   Devinsky, Orrin ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABIDIVARIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CARBAMAZEPINE; CLOBAZAM; DRONABINOL; NABILONE; NABIXIMOLS; PHENYTOIN; PLACEBO; TETRAHYDROCANNABINOLIC ACID; TOPIRAMATE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; VALPROIC ACID; ANTICONVULSIVE AGENT; CANNABINOID; MEDICAL CANNABIS;

ABNORMAL LABORATORY RESULT; ANTICONVULSANT ACTIVITY; BRAIN DEVELOPMENT; COGNITIVE DEFECT; DECISION MAKING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ABUSE; DRUG EFFICACY; DRUG FATALITY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; FATIGUE; GENERALIZED EPILEPSY; HALLUCINATION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTELLIGENCE QUOTIENT; LIVER FUNCTION TEST; LOW DRUG DOSE; MEMORY DISORDER; MOOD CHANGE; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NAUSEA; NERVE EXCITABILITY; NONHUMAN; PAIN; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SUICIDAL IDEATION; SYNAPSE; SYSTEMATIC REVIEW; TERATOGENICITY; TONIC CLONIC SEIZURE; TRAFFIC ACCIDENT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; WEAKNESS; WEIGHT REDUCTION; ANIMAL; CHEMISTRY;

ANIMALS; ANTICONVULSANTS; CANNABIDIOL; CANNABINOIDS; CANNABIS; DRONABINOL; EPILEPSY; HUMANS; MEDICAL MARIJUANA;

EID: 84941299566     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1407304     Document Type: Review

References (77)

1. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78: 1548-54.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
3. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol 2012; 11: 792-802.
4. Gupta S. Weed. In: Gupta S, ed. CNN, 2013 (see video promotion for program at http://www.cnn.com/videos/bestoftv/2013/08/05/gupta-weed-promo .cnn).
5. Schultes RE. Man and marihuana. Nat Hist 1973; 82: 59.
6. Gowers WR. Epilepsy and other chronic convulsive disorders. London: Churchill, 1881.
7. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
8. ElSohly M, Gul W. Constituents of cannabis sativa. In: Pertwee R, ed. Handbook of cannabis. Oxford, United Kingdom: Oxford University Press, 2014: 3-22.
9. Cascio MG, Pertwee RG. Known pharmacological actions of nine nonpsychotropic phytocannabinoids. In: Pertwee RG, ed. Handbook of cannabis. Oxford, United Kingdom: Oxford University Press, 2014: 137.
10. Pertwee RG, Cascio MG. Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chem-ical constituents of cannabis that activate cannabinoid receptors. In: Pertwee RG, ed. Handbook of cannabis. Oxford, United Kingdom: Oxford Unversity Press, 2014: 115.
11. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 2012; 76: 70-81.
12. Romigi A, Bari M, Placidi F, et al. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia 2010; 51: 768-72.
13. Ludányi A, Eross L, Czirják S, et al. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 2008; 28: 2976-90.
14. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 84-8.
15. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ. Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett 2007; 411: 11-6.
16. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol 2007; 558: 52-9.
17. Monory K, Massa F, Egertová M, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006; 51: 455-66.
18. Guggenhuber S, Monory K, Lutz B, Klugmann M. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One 2010; 5(12): e15707.
19. Karanian DA, Karim SL, Wood JT, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther 2007; 322: 1059-66.
20. Hill AJ, Hill TDM, Whalley BJ. The development of cannabinoid based therapies for epilepsy. In: Murillo-Rodríguez E, Onaivi ES, Darmani NA, Wagner E, eds. Endocannabinoids: molecular, pharmacological, behavioral and clinical features. Sharjah, United Arab Emirates: Bentham Science, 2013: 164-204.
21. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003; 307: 129-37.
22. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014; 55: 791-802.
23. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
24. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163: 1479-94.
25. Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid-and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A 2013; 110: 5193-8.
26. Campos AC, Ferreira FR, Guimar.es FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res 2012; 46: 1501-10
27. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006; 103: 7895-900.
28. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95: 8268-73.
29. Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 2013; 170: 679-92.
30. Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 2014; 5: 1131-41.
31. Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry 1990; 51: 439-40.
32. Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis 2007; 4: 103-6.
33. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014; 55: 783-6.
34. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015; 45: 49-52.
35. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; 3: CD009270.
36. Davis JP, Ramsey HH. Anti-epileptic action of marijuana-active substances. Fed Proc, Am Soc Exp Biol 1949; 8: 284.
37. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978; 65: 174-9.
38. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-85.
39. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986; 69: 14
40. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Presented at the Marijuana '90 International Conference on Cannabis and Cannabinoids, Kolympari, Crete, July 8-11, 1990. abstract.
41. Devinsky O, Sullivan J, Friedman D, et al. Epidiolex (cannabidiol) in treatment resistant epilepsy. Presented at the annual meeting of the American Academy of Neurology, Washington, DC, April 18-25, 2015. abstract.
42. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013; 29: 574-7.
43. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use: case report. Dis Nerv Syst 1967; 28: 474-5.
44. Consroe PF, Wood GC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975; 234: 306-7.
45. Gross DW, Hamm J, Ashworth NL, Quigley D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004; 62: 2095-7.
46. Hamerle M, Ghaeni L, Kowski A, Weissinger F, Holtkamp M. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol 2014; 21: 167-70.
47. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82: 1556-63.
48. Brust JC, Ng SK, Hauser AW, Susser M. Marijuana use and the risk of new onset seizures. Trans Am Clin Climatol Assoc 1992; 103: 176-81.
49. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42: 1266-72.
50. Hegde M, Santos-Sanchez C, Hess CP, Kabir AA, Garcia PA. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav 2012; 25: 563-6.
51. Feeney DM. Marihuana use among epileptics. JAMA 1976; 235: 1105.
52. Tofighi B, Lee JD. Internet highs - seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 2012; 6: 240-1.
53. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611-6.
54. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219-27.
55. Lorenzetti V, Solowij N, Whittle S, et al. Gross morphological brain changes with chronic, heavy cannabis use. Br J Psychiatry 2015; 206: 77-8.
56. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012; 109: E2657-E2664.
57. Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci U S A 2013; 110: 4251-4.
58. Behnke M, Smith VC. Prenatal substance abuse: short-and long-term effects on the exposed fetus. Pediatrics 2013; 131(3): e1009-e1024.
59. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9.
60. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabisbased medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14(3): 290-6.
61. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20(2): 567-73.
62. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-52.
63. Bergamaschi MM, Queiroz RHC, Zuardi AW, Crippa JAS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011; 6: 237-49.
64. Schoedel KA, Chen N, Hilliard A, et al. A randomized, double-blind, placebocontrolled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 2011; 26: 224-36.
65. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 2014; 46: 86-95.
66. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-56.
67. Friedman D, Cilio MR, Tilton N, et al. The effect of epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. Presented at the annual meeting of the American Epilepsy Society, Seattle, December 5-9, 2014. abstract.
68. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr 2013; 167: 630-3.
69. Healy J. Odd byproduct of legal marijuana: homes that blow up. New York Times. January 18, 2015: A1 (http://www .nytimes .com/2015/01/18/us/odd-byproduct-of-legal-marijuana-homes-blow-up .html? -r=0).
70. Drug Enforcement Agency. Drug scheduling: drug schedules (http://www .dea .gov/druginfo/ds.shtml).
71. Robson P. Abuse potential and psychoactive effects of d-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675-85.
72. Mathern GW, Beninsig L, Nehlig A. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey. Epilepsia 2015; 56: 1-6.
73. Henderson GE, Churchill LR, Davis AM, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med 2007; 4(11): e324.
74. Devinsky O. Medical marijuana survey and epilepsy. Epilepsia 2015; 56: 7-8.
75. Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P. Placebo effects in children: a review. Pediatr Res 2013; 74: 96-102.
76. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 2008; 5(8): e166.
77. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77: 1473-81.